Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Pancreatic Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Gemcitabine 19130-nm albumin-bound paclitaxel 16Specimen Handling 15Irinotecan 11Magnetic Resonance Spectroscopy 10Fluorouracil 10Leucovorin 9Biopsy 9Oxaliplatin 8pembrolizumab 7Cyclophosphamide 7fludarabine 6Cisplatin 5Pemetrexed 4Cetuximab 4Albumin-Bound Paclitaxel 4zimberelimab 3trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3durvalumab 3dehydroftorafur 3aldesleukin 3Taxes 3Radiosurgery 3Nivolumab 3Immunoglobulin G 3Disulfides 3Carboplatin 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × IFL protocol × 30 days × Clear all
NCT05419479 2026-06-04

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡